While several major biotech companies are laying off employees by the hundreds, one is dropping billions in acquisitions.

Locking in profits while you have them can help avoid downturns.

Discover the best biotech ETFs to diversify your portfolio, gain exposure to cutting-edge biotech innovations, and reduce risk in a volatile sector.

Corcept Therapeutics Inc. (NASDAQ: CORT) is one of the 10 best biotech stocks with highest upside potential.

Eli Lilly’s run of near-weekly acquisitions still shows no sign of letting up, with the Big Pharma now buying Ajax ...

Following a turbulent year for the markets in general and biotech in particular, the industry made a notable recovery, ...

Biopharma is rebounding across rare disease, oncology and neuroscience. Here, Cytokinetics achieved a rare milestone: a first ...

The 552 million pounds ($747 million) raised by British biotechs in the first quarter of the year has been hailed as a “sign ...

After Xoma Royalty went on a dealmaking spree last year, the biotech royalty aggregator is now itself being bought out by its ...

Global biotech mergers and acquisitions are on track for one of their biggest years ever, with $84 billion in deals announced in the first quarter of 2026. Large pharmaceutical companies are racing to ...

Young biotechs usually get acquired instead of profitably selling their own medicines. A growing number are proving they can, ...

Dallas‑based Colossal Biosciences, known for its woolly mammoth work, has announced its next de‑extinction effort—aiming to ...